Health Sector Shifts: Cancer Deals, Supplement Sales, and Drug Approvals
Published on: April 11, 2026, 10:28 a.m. | Source: Devdiscourse
C4 Therapeutics, in collaboration with Roche, embarks on a billion-dollar cancer drug venture. Meanwhile, AG1 considers selling the company or a minority stake to strategize future growth. FDA scrutiny compels Granules India to enhance oversight, and genetic variations affect the response to GLP-1 obesity drugs. Estrogen patch shortages worry patients.
